Global Microbial Fermentation Technology Market to Increase at a Steady Growth Rate of ~5% by 2032 | DelveInsight

The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer and infectious conditions such as HIV, hepatitis B and C, and influenza. Moreover, the growing demand for cutting-edge treatments, including cell therapies, monoclonal antibodies, recombinant proteins, and gene therapies, is further accelerating market expansion.

New York, USA, March 03, 2025 (GLOBE NEWSWIRE) — Global Microbial Fermentation Technology Market to Increase at a Steady Growth Rate of ~5% by 2032 | DelveInsight

The microbial fermentation technology market is experiencing significant growth, fueled by the increasing incidence of chronic diseases like cancer and infectious conditions such as HIV, hepatitis B and C, and influenza. Moreover, the growing demand for cutting-edge treatments, including cell therapies, monoclonal antibodies, recombinant proteins, and gene therapies, is further accelerating market expansion.

DelveInsight’s Microbial Fermentation Technology Market Insights report provides the current and forecast market analysis, individual leading microbial fermentation technology companies’ market shares, challenges, microbial fermentation technology market drivers, barriers, trends, and key market microbial fermentation technology companies in the market.

Key Takeaways from the Microbial Fermentation Technology Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global microbial fermentation technology market during the forecast period. 
• In the product type segment of the microbial fermentation technology market, the antibiotics category held the largest revenue share in 2024.
• Notable microbial fermentation technology companies such as Novozymes A/S, Lonza Group AG, Koninklijke DSM N.V., Biocon Limited, Ajinomoto Co., Inc., Evonik Industries AG, Intralytix, Inc., UAS Laboratories LLC, Second Genome, Inc., Chr. Hansen Holding A/S, Ginkgo Bioworks, Amyris, Inc., Lesaffre, BioVectra Inc.TerraVia Holdings, Inc., and several others, are currently operating in the microbial fermentation technology market.
• In June 2024, Danone, Michelin, DMC Biotechnologies, and Crédit Agricole Centre France collaborated to establish the Biotech Open Platform, a cutting-edge biotechnology hub aimed at advancing large-scale precision fermentation. This initiative enhanced the development of bio-based materials and ingredients by leveraging advanced microbial fermentation processes.
• In March 2024, Novel Bio, a leader in next-generation biomanufacturing technologies for plasmid DNA in genetic medicines, announced a partnership with Culture Biosciences to advance scalable fermentation process development for its proprietary NBx Platform™.

To read more about the latest highlights related to the microbial fermentation technology market, get a snapshot of the key highlights entailed in the Global Microbial Fermentation Technology Market Report

Microbial Fermentation Technology Overview

Microbial fermentation technology harnesses the metabolic processes of microorganisms such as bacteria, fungi, and yeast to produce valuable products. This technique is widely used in various industries, including pharmaceuticals, food and beverages, biofuels, and agriculture. Through controlled fermentation, microbes can convert raw materials into antibiotics, enzymes, organic acids, and biopolymers. Advances in genetic engineering and bioprocess optimization have enhanced microbial fermentation, making it more efficient and sustainable. This technology plays a crucial role in the production of biologics, probiotics, and bio-based chemicals, reducing reliance on synthetic processes and contributing to a greener economy.  

In the pharmaceutical industry, microbial fermentation is essential for producing antibiotics like penicillin, as well as therapeutic proteins, vaccines, and monoclonal antibodies. In food production, it is used to create products such as yogurt, cheese, and alcoholic beverages. With growing interest in sustainable solutions, microbial fermentation is also being explored for biodegradable plastics and alternative protein sources. The development of precision fermentation, which uses engineered microbes to produce specific molecules, is further revolutionizing the field. As research continues, microbial fermentation technology is expected to drive innovations in medicine, nutrition, and environmental sustainability.

Microbial Fermentation Technology Market Insights

North America is expected to lead the microbial fermentation technology market from 2025 to 2032. This dominance is driven by several key factors, including the increasing prevalence of infectious diseases (such as tuberculosis, influenza, and emerging pathogens), a rising cancer burden, strong product development initiatives, the presence of major manufacturers, and a well-established healthcare infrastructure.  

The growing incidence of cancer in North America further propels market expansion. According to the National Cancer Institute (2024), the U.S. is projected to see 2 million new cancer cases by the end of 2024. Additionally, data from the Global Cancer Observatory (2024) indicates that in 2022, the U.S. accounted for 89% of all cancer cases in the region, while Canada represented 11%. This increasing cancer prevalence has intensified the demand for microbial fermentation technologies used in the production of biopharmaceuticals, monoclonal antibodies, recombinant proteins, and gene therapies. The rising adoption of plasmid DNA, viral vectors, and microbiome-based treatments—especially in oncology—is driving the expansion of fermentation-based biomanufacturing. As precision medicine and immunotherapies continue to advance, the need for scalable and high-quality fermentation technologies for therapeutic production is growing.  

Furthermore, North America benefits from the presence of leading industry players who are actively innovating in microbial fermentation technologies. Companies in the region are enhancing bioprocesses through AI-driven bioreactors, bioprocess optimization, and synthetic biology, improving efficiency, product yield, and cost-effectiveness. Additionally, the region’s strong healthcare infrastructure, coupled with robust regulatory support and government funding, accelerates the research, development, and commercialization of fermentation-based products.  

Together, these factors create a highly favorable environment for market growth, solidifying North America’s position as the dominant region in the microbial fermentation technology market during the forecast period (2025–2032).

To know more about why North America is leading the market growth in the microbial fermentation technology market, get a snapshot of the Microbial Fermentation Technology Market Outlook 

Microbial Fermentation Technology Market Dynamics

The microbial fermentation technology market is witnessing significant growth, driven by increasing demand across various industries, including pharmaceuticals, food & beverages, agriculture, and biofuels. Advances in synthetic biology, metabolic engineering, and bioprocess optimization have enhanced microbial fermentation’s efficiency, making it a viable alternative to traditional chemical synthesis. With the rise of biopharmaceuticals, particularly monoclonal antibodies, vaccines, and recombinant proteins, microbial fermentation plays a crucial role in enabling large-scale production. Additionally, the shift toward sustainable and eco-friendly production methods is further fueling the adoption of microbial fermentation technologies.

One of the primary drivers of this market is the increasing demand for biologics and biosimilars in the pharmaceutical sector. The growing prevalence of chronic diseases and the need for cost-effective biologic drugs have accelerated investments in microbial fermentation-based drug production. Companies are leveraging microbial strains like Escherichia coli and Saccharomyces cerevisiae to manufacture high-value therapeutics. Additionally, the expansion of cell-culture-based vaccine production, as seen with COVID-19 vaccines, has strengthened the market’s growth trajectory.

In the food and beverage sector, microbial fermentation is revolutionizing alternative proteins and probiotics. The surge in plant-based and cultured food products has led to increased R&D in precision fermentation, where microbes produce dairy and meat analogs without relying on animal agriculture. The rising health consciousness among consumers and the demand for functional foods with probiotic benefits further contribute to the market’s expansion. Additionally, fermentation-based food preservation methods are gaining traction as clean-label and natural food trends continue to grow.

However, the market faces challenges, including high production costs, regulatory complexities, and scalability issues. The initial capital investment required for fermentation infrastructure, along with stringent compliance requirements for biopharmaceutical production, poses entry barriers for smaller players. Additionally, optimizing microbial strains for enhanced yield and purity while maintaining cost-effectiveness remains a technical challenge. Despite these hurdles, advancements in bioprocessing technologies, AI-driven strain optimization, and automation are gradually overcoming these limitations.

Looking ahead, strategic collaborations and innovations in fermentation technology will shape the market’s future. Key players are investing in synthetic biology startups, developing engineered microbes, and exploring novel applications such as biofuels, biomaterials, and agricultural biostimulants. As industries increasingly pivot toward sustainability, microbial fermentation will play a pivotal role in creating bio-based alternatives to petroleum-derived products, further solidifying its market potential.

Get a sneak peek at the microbial fermentation technology market dynamics @ Microbial Fermentation Technology Market Dynamics Analysis

Microbial Fermentation Technology Market Assessment

• Microbial Fermentation Technology Market Segmentation
  • Microbial Fermentation Technology Market Segmentation By Product Type: Antibiotics, Probiotics, Monoclonal Antibodies, Biosimilar, Recombinant Proteins & Vaccines, Enzymes, and Others
  • Microbial Fermentation Technology Market Segmentation By End-User: Pharmaceutical & Biotechnology Industry, Contract Research Organizations (CROs), CMOs & CDMOs, and Academic & Research Institutions
  • Microbial Fermentation Technology Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the microbial fermentation technology market are set to emerge as the trendsetter explore @ Microbial Fermentation Technology Companies 

Table of Contents 

Interested in knowing the microbial fermentation technology market by 2032? Click to get a snapshot of the Microbial Fermentation Technology Market Trends

Related Reports

Contract Development Manufacturing Organization Market

Contract Development Manufacturing Organization Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CDMO companies, including Patheon (Thermo Fisher Scientific), Catalent,Inc, Laboratoire Elaiapharm, The Lubrizol Corporation, Cambrex Corporation, Recipharm (EQT), Merck & Co., Inc, AGC Biologics, Nerpharma S.r.l, Pfizer CenterOne (Pfizer Inc), EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Center for Breakthrough Medicines, and WuXi Biologics, among others.

Biopharmaceuticals Contract Manufacturing Market

Biopharmaceuticals Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biopharmaceuticals contract manufacturing companies, including Boehringer Ingelheim International GmbH, Lonza, Rentschler Biopharma SE, BINEX Co., Ltd., INCOG BioPharma Service, FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Novartis AG, ProBioGen AG, TOYOBO CO., LTD., Samsung Biologics, Thermo Fisher Scientific, Inc., AbbVie, Inc., WuXi Biologics, AGC Biologics, ADMA Biologics, Inc., Baxter BioPharma Solutions (Baxter), iBio., Catalent, Inc., Cambrex Corporation, Pfizer Inc., among others.

Biologics Drug Substance Fill and Finish Manufacturing Market

Biologics Drug Substance Fill and Finish Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance fill and finish manufacturing companies, including JOINN Biologics, Pharmaron, Symbiosis Pharmaceutical Services, AGC Biologics, INCOG BioPharma Services, CPC, Eurofins Scientific, among others.

Biologics Drug Substance Manufacturing Market

Biologics Drug Substance Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance manufacturing companies, including Lonza, Pfizer Inc., Catalent, Inc., Boehringer Ingelheim International GmbH, Samsung Biologics, WuXi AppTec, Thermo Fisher Scientific Inc., Asahi Kasei Corporation, Recipharm AB, Evotec, Novo Nordisk A/S, Siegfried Holding AG, Enzene Biosciences Ltd., Forge Biologics, BeiGene LTD., FUJIFILM Holdings Corporation, TOYOBO CO., LTD., AJINOMOTO CO., INC., Biocon, Eurofins Scientific, among others.

Biologics Contract Manufacturing Market

Biologics Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biologics contract manufacturing companies, including Boehringer Ingelheim, Catalent, Lonza, WuXi Biologics, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie, AGC Biologics, among others.

DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.

Other Business Consulting Services

Healthcare Conference Coverage

Pipeline Assessment

Healthcare Licensing Services

Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679 

• Author
• Recent Posts

GlobeNewswire

GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Latest posts by GlobeNewswire (see all)

• Ad.Com Acquires Public Good to Scale Purpose-Based Digital Advertising and AI Innovation - July 1, 2025
• Community Impact Coalition Issues Statement Applauding Senate Finance Committee’s Approach to Tax Treatment for Nonprofits - July 1, 2025
• Goodin Development Breaks Ground on The Elwood: $26 Million Mixed-Use Development to Transform Downtown Kokomo - July 1, 2025